Navigation Links
Efficacy Data from Phase III VELOUR Trial in Colorectal Cancer to be Presented at Angiogenesis Foundation's 2011 M. Judah Folkman International Conference in Cambridge, Mass.
Date:9/23/2011

CAMBRIDGE, Mass., Sept. 23, 2011 /PRNewswire/ -- Efficacy and safety data from VELOUR, the pivotal Phase III trial of aflibercept (VEGF Trap, ZALTRAP™) for the treatment of metastatic colorectal cancer (mCRC) will be presented by Edith P. Mitchell, M.D., a leading cancer researcher, at the Angiogenesis Foundation's 9th Annual M. Judah Folkman International Conference: Antiangiogenesis: New Frontiers in Therapeutic Development on October 29-30, 2011 at the Hyatt Regency Cambridge.

The VELOUR presentation will be the first time the results are presented in the U.S.

Registration for the conference is now open. To review the topic and speaker agenda visit http://www.angio.org/programs-cp-aa11.php.

Dr. Mitchell will join a roster of distinguished speakers at the conference, including Dr. Robert S. Kerbel of the University of Toronto, and Dr. Adriana Albini of IRCCS Multimedica, Italy.

This year's conference will include presentations by leaders from Harvard Medical School, the U.S. National Cancer Institute, University of Texas MD Anderson, Memorial Sloan Kettering Cancer Center, Stanford University, Queen's University Belfast, Johannes Gutenberg University Mainz, IRCCS Multimedica Milan, and other top research institutions.

Topics to be covered at this year's meeting include:

  • Anti-VEGF therapy resistance and antiangiogenic escape
  • VEGF-independent tumor angiogenesis
  • Glioblastoma vasculature and stem cells
  • Novel therapy biomarkers
  • Early intervention and prevention through antiangiogenesis

As the world's leading non-profit organization dedicated to advancing the field of angiogenesis research, the Angiogenesis Foundation takes a multidisciplinary approach to its annual conference, bringing together experts and key stakeholders from basic research, life sciences industry, clinical investigation, and government to foster new collaborations and exchanges between faculty and attendees.

Due to limited space, early registration is encouraged. For additional information please contact, Michelle Sylvanowicz at (617) 401-2779.


'/>"/>
SOURCE The Angiogenesis Foundation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
2. New Study Supports Efficacy of Vagus Nerve Stimulation for Treatment-Resistant Depression
3. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
4. Five-Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus(R) Stent Compared to Bare-Metal Stent
5. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
6. Ortho Biotech Reiterates Confidence in PROCRIT(R) (Epoetin alfa) Safety and Efficacy When Used According to Label
7. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
8. New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy
9. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
10. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/28/2017)... Sept. 28, 2017 Cohen Veterans Bioscience and ... use of wearable and home sensors for real-time monitoring ... Signal Foundation, a nonprofit organization focused on disruptive health ... an affordable analytical system to record and integrate behavioral, ... ...
(Date:9/25/2017)... 2017  EpiVax, Inc., a leader in the ... today announced the launch of EpiVax Oncology Inc., ... therapeutic cancer vaccines. EpiVax has provided $500,000 in ... enabling technologies to the new precision immunotherapy venture. ... Oncology as Chief Executive Officer. Gad brings over ...
(Date:9/19/2017)... ANN ARBOR, Mich. , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical ... the precise destruction of targeted tissues, announced three leadership team developments today:   ... Josh Stopek, PhD ... ... Veteran medical device executive ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... Ellevate Network, the leading network for professional women, brought together some of ... their inaugural Summit in New York City in June. The event was livestreamed with ... 3 million. To watch the Mobilize Women video, click here . , ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, actor Rob Lowe, ... in a new episode of "Success Files," which is an award-winning educational program ... investigates each subject in-depth with passion and integrity. , Sciatica occurs when the ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... “America On ... Christian identity. “America On The Brink” is the creation of published author, William ... several great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
(Date:10/12/2017)... ... , ... Planet Fitness, one of the largest and fastest growing franchisors and ... flagship location in Covington, LA at 401 N. U.S. Highway 190, in January of ... Depot in the Holiday Square shopping center. Its location allows it to serve both ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of ... Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, ... In honor of Morris F. Collen, a pioneer in the field of medical informatics, ...
Breaking Medicine News(10 mins):